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Background: Several imaging techniques may reveal calciﬁ  cation of the arterial wall or 
cardiac valves. Many studies indicate that the risk for cardiovascular disease is increased when 
calciﬁ  cation is present. Recent meta-analyses on coronary calciﬁ  cation and cardiovascular risk 
may be confounded by indication. Therefore, this meta-analysis was performed with extensive 
subgroup analysis to assess the overall cardiovascular risk of ﬁ  nding calciﬁ  cation in any arterial 
wall or cardiac valve when using different imaging techniques.
Methods and results: A meta-analysis of prospective studies reporting calciﬁ  cations and 
cardiovascular end-points was performed. Thirty articles were selected. The overall odds ratios 
(95% conﬁ  dence interval [CI]) for calciﬁ  cations versus no calciﬁ  cations in 218,080 subjects 
after a mean follow-up of 10.1 years amounted to 4.62 (CI 2.24 to 9.53) for all cause mortality, 
3.94 (CI 2.39 to 6.50) for cardiovascular mortality, 3.74 (CI 2.56 to 5.45) for coronary events, 
2.21 (CI 1.81 to 2.69) for stroke, and 3.41 (CI 2.71 to 4.30) for any cardiovascular event. 
Heterogeneity was largely explained by length of follow up and sort of imaging technique. 
Subgroup analysis of patients with end stage renal disease revealed a much higher odds ratio 
for any event of 6.22 (CI 2.73 to 14.14).
Conclusion: The presence of calciﬁ  cation in any arterial wall is associated with a 3–4-fold 
higher risk for mortality and cardiovascular events. Interpretation of the pooled estimates has 
to be done with caution because of heterogeneity across studies.
Keywords: calciﬁ  cation, cardiovascular risk, meta-analysis, imaging
Introduction
Several imaging techniques may reveal vascular calcium deposits. Since these deposits are 
not always the prime reason for the investigation, the presence of calciﬁ  ed blood vessel 
walls or heart valves is often not recognized as a clinically important sign of vascular risk. 
Although calciﬁ  cations may occur in small amounts in the earlier stages of atherosclerosis, 
they are usually seen in more advanced lesions.1 Indeed, various studies have observed 
an increased cardiovascular risk in patients with calciﬁ  cation.2–8 However, the latter is 
not a uniform ﬁ  nding.9 This discrepancy may be due to differences in methodology, 
patient selection and baseline risk. Recent meta-analyses of the relationship between 
calciﬁ  cation and vascular risk have focused exclusively on coronary calcium scores.10 
As patients with coronary insufﬁ  ciency are more likely to be subjected to diagnostic 
imaging than others, part of the relationship between coronary calciﬁ  cation and outcome 
may be confounded by indication. To overcome this problem, we performed the present 
meta-analysis in which we assessed the impact of calcium deposits in any artery or heart 
valve, with different imaging techniques, on fatal and nonfatal cardiovascular events as 
well as total mortality in populations with different baseline risks.
Methods
To identify studies on vascular calciﬁ  cation (mineralization detected in any part of the 
blood vessel wall or heart valves) and cardiovascular risk, a PubMed, Embase, and Vascular Health and Risk Management 2009:5 186
Rennenberg et al
Cochrane library search was performed using the following 
search terms: “plain radiography or chest X-ray or abdominal 
X-ray or mammography or panoramic radiography or 
ultrasound (US) or computer tomography (CT) or magnetic 
resonance imaging (MRI)” and (cardiovascular risk or 
calciﬁ  cation). Two investigators (RJMW Rennenberg and AA 
Kroon) screened all abstracts and, after applying the criteria 
for eligibility, decided on whether or not the full papers should 
be retrieved. All authors reviewed qualifying papers.
Study eligibility
Only prospective cohort studies were eligible. Paediatric 
studies were excluded. Articles published between 1970 and 
June 2008, with prospective data on human vascular calciﬁ  -
cation and well-documented end-points were selected. Case 
reports were excluded. Data on events in both groups, with 
and without calciﬁ  cation, had to be reported separately. To be 
selected for the analysis absolute numbers, ie, a two-by-two 
table, should be extractable from the text. References found 
in the selected papers that fulﬁ  lled these criteria were also 
selected. Only papers published in English, German, Dutch, 
and French were considered. When data were published in 
consecutive articles by the same authors only the article with 
the most comprehensive dataset was considered.8,11–13
Deﬁ  nition of end-points
End-points were deﬁ  ned as all cause mortality, cardio-
vascular mortality (death from any cardiovascular cause), 
coronary event (myocardial infarction, coronary mortality, 
percutaneous coronary angioplasty or coronary artery bypass 
operation), stroke (ischemic and hemorrhagic) and any 
cardiovascular event (cardiovascular mortality, coronary 
event, stroke, peripheral revascularisation procedures or 
amputation, carotid endarterectomy).
Statistical analysis
Studies reporting data suitable to make two by two tables 
of calciﬁ  cation in relation to events were used to compute 
odds ratio’s using a random effects meta-analysis. Because 
we expected signiﬁ  cant heterogeneity, a meta-regression 
analysis with a random effect model was performed, as 
suggested by Egger and colleagues,14 taking into account the 
following variables: duration of follow up, type of imaging 
technique (plain radiograph, CT, or US) and baseline risk 
of the population, estimated as low (asymptomatic without 
known cardiovascular risk factors), intermediate (asymp-
tomatic with one or more cardiovascular risk factors or 
diabetes but no renal insufﬁ  ciency) and high (symptomatic 
or renal insufﬁ  ciency). Publication bias was assessed with 
a funnel plot of the risk for any cardiovascular event. Sta-
tistical calculations were done using the STATA statistical 
program version 8.2 (StataCorp, College Station, TX), with 
the latest updates.
Results
We originally retrieved over 2,500 articles. Screening 
of abstracts and exclusion of case-reports resulted in 
91 remaining original studies on the association between 
human vascular or valvular calciﬁ  cations and cardiovas-
cular risk. After applying the eligibility criteria 61 studies 
were excluded mainly because they were not prospective 
follow up studies. Only a few studies were excluded because 
absolute numbers could not be extracted or results were not 
reported as calciﬁ  cation versus no calciﬁ  cation. The remain-
ing 30 studies, which are summarized in Table 1, could be 
included.3,5–9,13,15–37 Ten studies concerned plain radiogra-
phy, such as mammograms, chest X-rays or X-rays of the 
peripheral blood vessels (eg, the femoral artery); ten studies 
had applied CT, mostly of the coronaries, and in 10 studies 
US had been used, predominantly of the heart valves. On 
plain radiographs vascular calciﬁ  cations were deﬁ  ned as 
linear densities in the blood vessel area. With CT vascular 
calciﬁ  cation was deﬁ  ned as any vessel part with a density 
of 130 Hounsﬁ  eld units or more. In the US studies highly 
echogenic plaques producing bright white echoes with shad-
owing were noted as calciﬁ  cations. No reports with respect 
to MRI fulﬁ  lled the inclusion criteria. In these 30 papers, 
the absolute numbers of events in relation to the presence or 
absence of calciﬁ  cations were reported, comprising a total of 
218,080 subjects. Overall, 53% of the subjects were males. 
The prevalence of vascular calciﬁ  cations varied according 
to the patient group studied. The lowest prevalence of 2.3% 
was found in an asymptomatic population with a mean age 
of 47 years in which aortic arch calciﬁ  cations on plain chest 
X-rays were studied.5 The highest prevalence of 88.9% was 
found in patients (mean age 56 years) with chest pain in 
whom coronary calciﬁ  cations were measured by electron 
beam computer tomography (EBCT).24 The median preva-
lence of calciﬁ  cation in all studies was 57.5%. The mean 
follow up to record the number of cardiovascular events in 
these studies was 10.1 years (range 2–26).
All cause mortality
In nine studies, with a total of 3,821 deaths among 
the 40,747 participants, data on all cause mortality were re
ported.11,17,19,22,27,28,33,36,37 Odds ratios are depicted in Figure 1. Vascular Health and Risk Management 2009:5 187
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Among 16,528 subjects with calciﬁ  cations 1,589 deaths 
were observed. Four of the studies comprised a popula-
tion with renal insufﬁ  ciency in which the event rate for all 
cause mortality in patients with calciﬁ  cations was more 
than 5 times higher than in patients without calciﬁ  cations. 
Overall OR for mortality from all causes was 4.62 (95% CI 
2.24 to 9.53, Figure 1). The odds ratio for all cause mortality 
in patients without renal insufﬁ  ciency was 3.43 (95% CI 
1.26 to 9.32).
Cardiovascular mortality
Odds ratios for cardiovascular mortality are also shown 
in Figure 1. A total of 1,356 cardiovascular deaths were 
observed among the 17,187 participants in the 9 studies that 
reported data on this complication.8,9,13,22,27,28,30,33,36 Among 
3,657 subjects with calcifications, 718 cardiovascular 
deaths were observed. In two of the nine studies the imag-
ing technique was US, one study employed CT, and in the 
remainder plain radiographs were used. The overall OR for 
cardiovascular mortality in the presence of calciﬁ  cations 
was 3.94 (95% CI 2.39 to 6.50), but there was signiﬁ  cant 
heterogeneity among the studies (Figure 1).
Coronary events
Data on coronary events were available in 16 studies 
(17,482 events among 173,650 subjects).3,5,6,8,15,16,22–24,28,29,31,33–35,38 
In the 19,261 subjects with calciﬁ  cations, 1,534 events were 
observed resulting in an overall OR of 3.74 (95% CI 2.56 to 
5.45; Figure 2). Eight of these studies had utilized CT-scans 
of the coronaries and four used plain radiography. Thirteen 
studies originated from a North American population and most 
of the studies were done for screening purposes in an asymp-
tomatic population. Average follow up in the CT-studies was 
only four years, but 18.7 years in the studies done with plain 
radiography.
Stroke
Stroke was reported as primary outcome in 11 studies 
with a total of 154,784 subjects of whom 9,889 showed 
calciﬁ  cations.5–8,18,25–28,33,39 In the group with calciﬁ  cations 
there were 874 stroke cases. The total number of events was 
10,454. Only one out of ﬁ  ve studies with ultrasound looked 
at calciﬁ  cations of the carotid artery, whereas in the other 
four US of the heart valves was performed. The remaining 
six studies, all with plain radiographs, evaluated vascular 
calciﬁ  cations of the breast, the thoracic or abdominal aorta 
and peripheral arteries. None of the studies with CT assessed 
the incidence of stroke. The overall OR for stroke was 
T
a
b
l
e
 
1
 
(
C
o
n
t
i
n
u
e
d
)
P
o
p
u
l
a
t
i
o
n
A
u
t
h
o
r
Y
e
a
r
 
o
f
 
p
u
b
l
i
c
a
t
i
o
n
N
u
m
b
e
r
 
o
f
 
s
u
b
j
e
c
t
s
M
e
a
n
 
f
o
l
l
o
w
 
u
p
 
M
a
l
e
 
(
%
)
M
e
a
n
 
a
g
e
(
Y
e
a
r
)
M
o
d
a
l
i
t
y
L
o
c
a
t
i
o
n
T
o
t
a
l
 
e
v
e
n
t
s
 
(
n
)
P
r
e
v
a
l
e
n
c
e
 
o
f
 
c
a
l
c
i
ﬁ
 
c
a
t
i
o
n
R
e
n
a
l
 
i
n
s
u
f
ﬁ
 
c
i
e
n
c
y
S
a
l
g
u
e
i
r
a
3
0
2
0
0
3
7
9

2
5
4
4
8
P
l
a
i
n
 
r
a
d
i
o
g
r
a
p
h
A
o
r
t
i
c
 
a
r
c
h
,
 
a
b
d
o
m
i
n
a
l
 
a
o
r
t
a
,
 
i
l
e
o
f
e
m
o
r
a
l
 
a
r
t
e
r
i
e
s
8
5
5
.
7
R
e
n
a
l
 
i
n
s
u
f
ﬁ
 
c
i
e
n
c
y
O
k
u
n
o
3
6
2
0
0
7
5
1
5
4
.
3
5
9
6
0
P
l
a
i
n
 
r
a
d
i
o
g
r
a
p
h
A
b
d
o
m
i
n
a
l
 
a
o
r
t
a
1
0
3
5
6
.
5
R
e
n
a
l
 
i
n
s
u
f
ﬁ
 
c
i
e
n
c
y
W
a
n
g
3
3
2
0
0
3
1
9
2
1
.
5
5
1
5
5
U
l
t
r
a
s
o
u
n
d
A
o
r
t
i
c
 
a
n
d
 
m
i
t
r
a
l
 
v
a
l
v
e
2
4
3
2
.
3
N
o
t
e
s
:
 
*
M
u
l
t
i
p
l
e
 
r
i
s
k
 
f
a
c
t
o
r
s
 
b
u
t
 
a
s
y
m
p
t
o
m
a
t
i
c
 
s
u
b
j
e
c
t
s
,
 
†
I
n
d
i
c
a
t
e
s
 
m
e
d
i
a
n
 
f
o
l
l
o
w
 
u
p
.
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
n
.
a
.
,
 
n
o
t
 
a
v
a
i
l
a
b
l
e
;
 
E
B
C
T
,
 
e
l
e
c
t
r
o
n
 
b
e
a
m
 
c
o
m
p
u
t
e
r
 
t
o
m
o
g
r
a
p
h
y
;
 
M
S
C
T
,
 
m
u
l
t
i
 
s
l
i
c
e
 
c
o
m
p
u
t
e
r
 
t
o
m
o
g
r
a
p
h
y
.Vascular Health and Risk Management 2009:5 189
Vascular calciﬁ  cations as a marker of cardiovascular risk
Blacher 2001
Fox 2003
Kemmeren 1998
Lehto 1996
London 2003
Wang 2003
Wilens 2006
Okuno 2007
Lehto 1996
London 2003
Wang 2003
Okuno 2007
Becker 2005
Overall (95% CI)
Niskanen 1994
Salgueira 2003
Overall (95% CI)
Fox 2003
Kemmeren 1998
Cardiovascular mortality
0.1 1 10
Odds ratio
Odds ratio
(95% CI) % Weight
Odds ratio
(95% CI)
12.30 (3.47,43.67) 7.1
15.0
16.3
15.7
9.3
11.8
11.1
13.7
3.16 (2.19,4.55)
1.43 (1.22,1.68)
2.14 (1.64,2.81)
15.16 (5.74,40.06)
4.51 (2.24,9.07)
3.04 (1.40,6.61)
3.54 (2.13,5.89)
3.52 (2.25,5.50)
% Weight
2.31 (1.60,3.34)
1.71 (1.29,2.27)
2.16 (1.59,2.94)
18.38 (4.30,78.47)
0.80 (0.40,1.62)
16.53 (0.92,297.31)
4.87 (1.94,12.23)
4.10 (1.78,9.44)
15.17 (0.92,249.54)
2.61 (1.74,3.92)
18.1
19.3
18.9
5.7
13.0
1.8
10.1
11.2
1.9
0.1 1 10
Odds ratio
All cause mortality
Figure 1 Odds ratios for mortality, all cause and cardiovascular, when calciﬁ  cation is present.
Notes: Heterogeneity for all cause mortality chi-squared = 248.98 (d.f. = 8) p = 0.000; Heterogeneity for cardiovascular mortality chi-squared = 61.52 (d.f. = 8) p = 0.000.
2.21 (95% CI 1.81 to 2.69) in the presence of calciﬁ  cations 
anywhere (Figure 2).
Any cardiovascular event
In 27 studies with a total of 192,205 patients and 34,958 events, 
the risk for any cardiovascular event could be studied 
(Figure 3).3,5–9,12,15,16,18,22–36,38,39 In the 27,921 subjects 
with calciﬁ  cations, 3,245 events were recorded. The average 
age was 59 years, but in the studies that reported the average 
age for the subjects with and without calciﬁ  cations sepa-
rately, age was signiﬁ  cantly higher in those with calciﬁ  cations 
(63 versus 56 years, p  0.05). The overall OR for any 
cardiovascular event with any modality was 3.41 (95% CI 
2.71 to 4.30). This could be subdivided in an OR of 2.14 (95% 
CI 1.65 to 2.77) for ultrasound studies, 3.01 (95% CI 2.16 to 
4.20) for plain radiographic studies, and 7.26 (95% CI 4.42 
to 11.92) for studies using CT as diagnostic modality.
Meta regression analysis
for any cardiovascular event
Meta-regression analysis with respect to the outcome of 
any cardiovascular event showed that the type of imaging Vascular Health and Risk Management 2009:5 190
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Figure 2 Odds ratios for coronary events and stroke, when calciﬁ  cation is present.
Notes: Heterogeneity for coronary events chi-squared = 154.86 (d.f. = 15) p = 0.000; Heterogeneity for stroke chi-squared = 21.67 (d.f. = 10) p = 0.017.
technique and the duration of follow up were signiﬁ  cant 
causes of heterogeneity. After stratifying for imaging tech-
nique and follow up, the meta-analysis showed substantially 
lesser or no signiﬁ  cant heterogeneity. Figure 4 is shown as an 
example for the CT studies. However, the number of studies 
per group was also much smaller giving rise to less chance 
for heterogeneity.
When data of high risk populations or populations with renal 
insufﬁ  ciency or diabetes mellitus were analyzed separately 
there was also no signiﬁ  cant heterogeneity (chi-squared = 1.52 
[d.f. = 4] p = 0.823, 3.59 [d.f. = 3] p = 0.309 and 0.98 [d.f. = 1] 
p = 0.322, respectively) (Figures 5, 6).
Subgroup analysis
Most studies have been performed in asymptomatic popula-
tions participating in a screening program. In some, however, 
the indication for the test was the presence of one or more 
cardiovascular risk factors. The pooled OR for any cardiovas-
cular event was 3.34 (95% CI 2.51 to 4.43) in studies with low 
baseline risk,3,5–8,15,16,18,22,23,25,26,31,32,35 3.65 (95% CI 1.87 to 7.12) Vascular Health and Risk Management 2009:5 191
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Figure 3 Risk for any cardiovascular event when calciﬁ  cation is present.
Notes: Heterogeneity chi-squared = 198.94 (d.f. = 26) p = 0.000.
for populations with intermediate risk9,13,27,29,34,38,39 and 4.20 
(95% CI 2.44 to 7.23) in high risk subjects (Figure 5).24,28,30,33,36 
There was no signiﬁ  cant heterogeneity in the latter group for 
the pooled estimate.
When only subjects with renal insufﬁ  ciency were considered 
the risk for any cardiovascular event in the presence of 
calciﬁ  cations was even higher (Figure 6).19,28,30,33,36 All patients 
were on hemodialysis except for the patients in one study who 
were on continuous ambulatory peritoneal dialysis.33 In these 
ﬁ  ve studies, comprising a total of 1098 persons, 124 events 
were observed. Among the 599 patients with calciﬁ  cations, 
104 had suffered an event. Odds ratios for any cardiovascular 
event were 6.22 (95% CI 2.73 to 14.14). This pooled estimate 
was without signiﬁ  cant heterogeneity. Although the conﬁ  dence 
intervals overlap, it seemed that the presence of calciﬁ  cations 
had the highest predictive power for a cardiovascular or a 
cerebrovascular event in subjects with renal insufﬁ  ciency.
Although three studies reported data from diabetic 
patients, only two of these gave sufﬁ  cient information to 
calculate odds ratios for cardiovascular mortality (2.27, 95% 
CI 1.70 to 3.04).9,27 Of 1,192 patients, 508 had calciﬁ  ca-
tions on plain radiography of the femoral arteries of which 
139 of a total of 236 events occurred in the patients with 
calciﬁ  cations.
Funnel plot
A funnel plot of the standard error of log odds ratio was per-
formed to assess a possible publication bias (Figure 7). This 
is based on the fact that the precision in the estimation, of the 
underlying effect of ﬁ  nding calciﬁ  cation on outcome, will 
increase as the sample size of component studies increases. 
Effect estimates from small studies will therefore scatter more 
widely at the right of the graph, with the spread narrowing 
among larger studies to the left of the graph. In the absence Vascular Health and Risk Management 2009:5 192
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Figure 6 Subgroup analysis for renal insufﬁ  ciency and diabetes mellitus.
Notes: Heterogeneity in the renal insufﬁ  ciency group chi-squared = 3.59 (d.f. = 3) p = 0.309; Heterogeneity in the diabetes mellitus group chi-squared = 0.98 (d.f. = 1) 
p = 0.322.
of bias, the plot would appear to be symmetrical. Although 
it appears to be rather symmetrical, there are no studies in 
the right lower quadrant suggesting publication bias of small 
studies without any or a positive effect of calciﬁ  cation on car-
diovascular events. However there was no bias using statistical 
tests for bias such as the Egger (weighted regression) method 
(p for bias 0.24) or the Begg (rank correlation) method.14
Discussion
The objective of this meta-analysis was to assess the risks 
associated with calciﬁ  cation of the arterial wall or cardiac 
valves, as observed with different imaging methods in 
populations with different baseline risk. We showed that the 
presence of calciﬁ  cation with any type of imaging technique 
in these populations harbors a 3–4 times increased risk for 
mortality and cardiovascular events.
The present meta-analysis has several limitations. 
Firstly, it was not possible to adjust for age in our analy-
sis, since age was not provided in all studies. Although 
calciﬁ  cation becomes more prevalent with age, we had to 
use unadjusted data to assess the general risk of calciﬁ  cation 
as seen on any mode of investigation. However, in almost 
all individual studies calciﬁ  cation was an independent risk 
factor. Adjustment for age did not change their outcome Vascular Health and Risk Management 2009:5 195
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Figure 7 Funnel plot of standard error of log(OR) for any cardiovascular event.
Notes: Begg’s funnel plot of published studies reporting any cardiovascular event. The fact that many studies are outside the 95% conﬁ  dence interval, indicated by the sloping 
lines, is caused by heterogeneity of the studies.
substantially. Secondly, the possibility of publication bias has 
to be considered. The asymmetry as seen in the funnel plot 
suggests that this could be the case for small studies with no 
signiﬁ  cant effect on any cardiovascular event with calciﬁ  ca-
tion. However, statistical tests did not indicate signiﬁ  cant 
publication bias. Furthermore, there was signiﬁ  cant heteroge-
neity among the studies that could largely be explained by the 
different investigational tools on the one hand and different 
duration of follow up on the other. For example, patients 
who are being evaluated by CT for coronary symptoms, 
run a substantially higher risk with a shorter time horizon 
than those in whom calciﬁ  cations are found accidentally. 
When we analyzed the risk for any cardiovascular event 
separately in relation to the type of imaging technique and 
time of follow-up (5 years and 5 years), heterogeneity 
disappeared for the US and CT studies (Figure 4), but 
signiﬁ  cant heterogeneity remained present in studies using 
plain radiography with follow-up longer than ﬁ  ve years. This 
persistent heterogeneity can possibly be explained by differ-
ences in population characteristics and calciﬁ  cation. In the 
studies with diabetic patients medial calciﬁ  cation was present 
in most cases. Medial calciﬁ  cation is associated with higher 
odds ratios for events than intimal calciﬁ  cations in diabetic 
patients and might thus be an explanation for persistent 
heterogeneity in radiographic studies with a long follow-up 
period.9 Also the range of follow up time in these populations 
was much greater (2–26 years in plain radiograph studies, 
1.5–16 in US studies, and 2.7–6.9 in CT studies).
With respect to selection mechanisms and baseline risk, 
subgroup analysis of a renal insufﬁ  ciency population showed 
the highest risk. CT data predicted the events best with the 
highest odds ratio. Moreover, when calcium was seen with 
coronary CT, events occurred after a relatively short follow 
up period. Although coronary calciﬁ  cations as detected by 
CT were associated with a greater risk of events than calci-
ﬁ  cation in other areas, the difference in study populations 
preclude meaningful conclusions about the superiority of CT 
relative to other imaging modalities. Moreover, compared 
with plain X-rays or ultrasound studies, noncontrasted CT 
scans and EBCT are likely to be more sensitive for detecting 
small amounts of calciﬁ  cation. Interestingly, in hemodialysis 
patients were plain radiography or US were used to detect 
calciﬁ  cations some of the highest odds ratios for all cause 
mortality and cardiovascular mortality were seen.19,28,30,33,36 
This might reﬂ  ect their lower sensitivity for detecting any 
calciﬁ  cation. Half of the studies that reported on all cause 
mortality concerned a high-risk patient group with renal 
insufﬁ  ciency. This inﬂ  uenced the odds ratio resulting in a 
relatively high risk for all cause mortality. Nevertheless, 
when we calculated the odds ratio for populations without 
renal insufﬁ  ciency, this was still signiﬁ  cantly increased (3.43; 
95% CI 1.26 to 9.32).Vascular Health and Risk Management 2009:5 196
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The results of this meta-analysis help to clarify the 
importance of calciﬁ  cation in all sorts of patients. Although 
the reported odds ratios should be interpreted with caution 
because of substantial heterogeneity across studies, it showed 
that in almost any case of calciﬁ  cation there is an increased 
cardiovascular risk. It is important to realize that subjects 
with vascular calciﬁ  cation are high-risk patients. Currently, 
however, there is no speciﬁ  c therapy to reduce these calci-
ﬁ  cations and no evidence to support a better cardiovascular 
outcome with calciﬁ  cation reduction, although data from 
animal research and from human cells in vivo on the actions 
of matrix Gla protein as an active calciﬁ  cation inhibitor show 
promising results.40–42 The use of statins reduces the cardio-
vascular event rate in almost all patient groups, but data on 
their calciﬁ  cation inhibiting properties are conﬂ  icting.43–48
To our knowledge, there are no studies exploring the 
effect of treating all cardiovascular risk factors in patients 
based only on the presence of calciﬁ  cations. However, 
extensive coronary calciﬁ  cations justify further investigations 
for coronary plaques. Therefore, we feel that the practicing 
physician is also justiﬁ  ed to screen subjects, in whom calci-
ﬁ  cations are accidentally detected, for treatable risk factors. 
If these are present, the cardiovascular risk according to risk 
charts should be assessed. If the outcome exceeds the thresh-
old deﬁ  ned in guidelines, the physician should take measures 
to reduce the cardiovascular risk of his or her patient.
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